Dr. Slovin on Approaches of Immunotherapy in Prostate Cancer

Susan F. Slovin, MD, PhD
Published: Wednesday, Aug 16, 2017



Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses approaches of immunotherapy for patients with prostate cancer.

It’s important to recognize that immunotherapy encompasses more than checkpoint inhibitors, explains Slovin. There is a wide variety of other approaches that fall under the category of immunotherapy, such as antibodies, chimeric antigen receptor T cells, and DNA vaccines.
 
SELECTED
LANGUAGE


Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses approaches of immunotherapy for patients with prostate cancer.

It’s important to recognize that immunotherapy encompasses more than checkpoint inhibitors, explains Slovin. There is a wide variety of other approaches that fall under the category of immunotherapy, such as antibodies, chimeric antigen receptor T cells, and DNA vaccines.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x